A “bionic pancreas” is a device that uses next-generation technology to automatically deliver insulin to diabetic patients. A recent multicenter, randomized trial has evaluated the safety and efficiency of the bionic pancreas in the management of type 1 diabetes. Here’s a quick summary. Published in N Engl J Med, 2022. Authors: Steven J.
Russell et al. What was the need for the study? Several automated and semiautomated insulin-delivery systems have been developed for maintaining the glycated hemoglobin goal of less than 7%. In contrast to the currently available semiautomated insulin-delivery systems, the bionic pancreas is advantageous as it is initialized based only on body weight, makes all dose decisions, delivers insulin autonomously, and also uses meal announcements without carbohydrate counting. Therefore, its efficacy and safety needed to be examined and compared to standard…
